DE08868549T1 - Zusammensetzung zur behandlung steriler entzündungen - Google Patents
Zusammensetzung zur behandlung steriler entzündungen Download PDFInfo
- Publication number
- DE08868549T1 DE08868549T1 DE08868549T DE08868549T DE08868549T1 DE 08868549 T1 DE08868549 T1 DE 08868549T1 DE 08868549 T DE08868549 T DE 08868549T DE 08868549 T DE08868549 T DE 08868549T DE 08868549 T1 DE08868549 T1 DE 08868549T1
- Authority
- DE
- Germany
- Prior art keywords
- pharmaceutical composition
- use according
- selenium
- strontium
- leucine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010061218 Inflammation Diseases 0.000 title claims abstract 6
- 230000004054 inflammatory process Effects 0.000 title claims abstract 6
- 239000000203 mixture Substances 0.000 title claims abstract 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 11
- 239000011651 chromium Substances 0.000 claims abstract 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract 10
- 239000011669 selenium Substances 0.000 claims abstract 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract 8
- 239000011572 manganese Substances 0.000 claims abstract 8
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract 5
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims abstract 5
- 229910052804 chromium Inorganic materials 0.000 claims abstract 5
- 229960000304 folic acid Drugs 0.000 claims abstract 5
- 235000019152 folic acid Nutrition 0.000 claims abstract 5
- 239000011724 folic acid Substances 0.000 claims abstract 5
- 229960003136 leucine Drugs 0.000 claims abstract 5
- 229910052711 selenium Inorganic materials 0.000 claims abstract 5
- 229910052712 strontium Inorganic materials 0.000 claims abstract 5
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims abstract 5
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims abstract 5
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims abstract 5
- 239000004472 Lysine Substances 0.000 claims abstract 4
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims abstract 4
- 150000002632 lipids Chemical class 0.000 claims abstract 4
- 229910052748 manganese Inorganic materials 0.000 claims abstract 4
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000011573 trace mineral Substances 0.000 claims abstract 4
- 235000013619 trace mineral Nutrition 0.000 claims abstract 4
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims abstract 2
- 208000011231 Crohn disease Diseases 0.000 claims abstract 2
- 208000001640 Fibromyalgia Diseases 0.000 claims abstract 2
- 235000019454 L-leucine Nutrition 0.000 claims abstract 2
- 239000004395 L-leucine Substances 0.000 claims abstract 2
- 201000004681 Psoriasis Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 229910052721 tungsten Inorganic materials 0.000 claims 4
- 239000010937 tungsten Substances 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 3
- 150000008575 L-amino acids Chemical class 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- 229960003121 arginine Drugs 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 235000009697 arginine Nutrition 0.000 claims 3
- 230000001272 neurogenic effect Effects 0.000 claims 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Verwendung von
a) L-Aminosäuren Arginin (Arg) oder Lysin (Lys) und Leucin (Leu),
b) Spurenelementen Chrom (Cr), Zinn (Sn), Selen (Se), Strontium (Sr), Vanadium (V), und Wolfram (W), und
c) Folsäure
zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung oder Vorbeugung einer sterilen Entzündung.
a) L-Aminosäuren Arginin (Arg) oder Lysin (Lys) und Leucin (Leu),
b) Spurenelementen Chrom (Cr), Zinn (Sn), Selen (Se), Strontium (Sr), Vanadium (V), und Wolfram (W), und
c) Folsäure
zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung oder Vorbeugung einer sterilen Entzündung.
Claims (11)
- Verwendung von a) L-Aminosäuren Arginin (Arg) oder Lysin (Lys) und Leucin (Leu), b) Spurenelementen Chrom (Cr), Zinn (Sn), Selen (Se), Strontium (Sr), Vanadium (V), und Wolfram (W), und c) Folsäure zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung oder Vorbeugung einer sterilen Entzündung.
- Verwendung nach Anspruch 1, dadurch gekennzeichnet, dass die pharmazeutische Zusammensetzung weiter Zink (Zn) umfasst.
- Verwendung nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass die pharmazeutische Zusammensetzung weiter Mangan (Mn) umfasst.
- Verwendung nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, dass die pharmazeutische Zusammensetzung weiter neurogene CNS-Lipide umfasst.
- Verwendung nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, dass die pharmazeutische Zusammensetzung Folgendes umfasst: a) jeweils 2 bis 5 g L-Arginin-Hydrochlorid und L-Leucin, b) jeweils 0,5 bis 9 mg Chrom-(Cr), Zinn-(Sn), Selen-(Se), Strontium-(Sr), Vanadium-(V) und Wolfram(W)-Salze und c) 1 bis 2 mg Folsäure.
- Verwendung nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, dass die pharmazeutische Zusammensetzung in Pulverform vorliegt.
- Verwendung nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, dass die pharmazeutische Zusammensetzung in der Form einer funktionellen Nahrungsmittelzusatz-Zusammensetzung vorliegt.
- Verwendung nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, dass die sterile Entzündung im Zusammenhang mit Krankheiten, ausgewählt aus einer Gruppe umfassend Fibromyalgie, Crohn'sche Krankheit, Psoriasis und Rheuma, steht.
- Pharmazeutische Zusammensetzung, dadurch gekennzeichnet, dass sie als einzige pharmazeutisch aktive Bestandteile Folgendes umfasst: a) L-Aminosäuren Arginin (Arg) oder Lysin (Lys) und Leucin (Leu), b) Spurenelemente Chrom (Cr), Zinn (Sn), Selen (Se), Strontium (Sr), Vanadium (V) und Wolfram (W), Zink (Zn) und Mangan (Mn) und c) Folsäure und d) neurogene CNS-Lipide.
- Pharmazeutische Zusammensetzung nach Anspruch 9, dadurch gekennzeichnet, dass sie weiter Serin (Ser) du Isoleucin (Ile) als einzige pharmazeutisch aktive Bestandteile umfasst.
- Verfahren zur Behandlung oder Vorbeugung einer sterilen Entzündung, wobei pharmazeutisch aktive Mengen von: a) L-Aminosäuren Arginin (Arg) oder Lysin (Lys) und Leucin (Leu), b) Spurenelementen Chrom (Cr), Zinn (Sn), Selen (Se), Strontium (Sr), Vanadium (V), Wolfram (W) und optional Zink (Zn) und/oder Mangan (Mn) und c) Folsäure und optional d) neurogenen CNS-Lipiden einem Patienten, der diese benötigt, verabreicht werden.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20075971 | 2007-12-28 | ||
| FI20075971A FI122450B (fi) | 2007-12-28 | 2007-12-28 | Koostumus steriilin inflammaation hoitoon |
| PCT/FI2008/050750 WO2009083643A2 (en) | 2007-12-28 | 2008-12-17 | Composition for treating sterile inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE08868549T1 true DE08868549T1 (de) | 2011-03-17 |
Family
ID=38951666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE08868549T Pending DE08868549T1 (de) | 2007-12-28 | 2008-12-17 | Zusammensetzung zur behandlung steriler entzündungen |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100291235A1 (de) |
| EP (1) | EP2234611B1 (de) |
| JP (1) | JP5378406B2 (de) |
| KR (1) | KR20100103856A (de) |
| CN (1) | CN101917983B (de) |
| AT (1) | ATE544450T1 (de) |
| AU (1) | AU2008345508B2 (de) |
| BR (1) | BRPI0821919A2 (de) |
| DE (1) | DE08868549T1 (de) |
| DK (1) | DK2234611T3 (de) |
| ES (1) | ES2381690T3 (de) |
| FI (1) | FI122450B (de) |
| HK (1) | HK1143539A1 (de) |
| IL (1) | IL206596A0 (de) |
| NZ (3) | NZ597976A (de) |
| PL (1) | PL2234611T3 (de) |
| RU (1) | RU2462244C2 (de) |
| WO (1) | WO2009083643A2 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010359375B2 (en) * | 2010-08-18 | 2014-01-30 | Colgate-Palmolive Company | Oral care product and methods of use and manufacture thereof |
| FI123756B (fi) * | 2010-09-21 | 2013-10-31 | Neurofood Ab Oy | Parannettu lisäravinne syövän hoitamiseksi tai ennaltaehkäisemiseksi |
| JP5837315B2 (ja) * | 2011-03-25 | 2015-12-24 | イーエヌ大塚製薬株式会社 | 炎症性疾患用栄養組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0737471A3 (de) * | 1995-04-10 | 2000-12-06 | L'oreal | Verwendung von Erdalkalimetallsalze als TNF-alpha Inhibitor in einer topischen Zusammensetzung und die so hergestellte Zusammensetzung |
| RU2156087C1 (ru) * | 1999-11-25 | 2000-09-20 | Товарищество с ограниченной ответственностью Фирма "Электронная медицина" | Биологически активная добавка |
| US20040241256A1 (en) * | 2002-12-05 | 2004-12-02 | Seymour Ehrenpreis | Medicinal compositions & therapeutic methods |
| ATE460168T1 (de) * | 2003-10-17 | 2010-03-15 | Neurofood Ab Oy | Nicht-radioaktives strontiummittel zur behandlung von krebs |
| FI121915B (fi) * | 2004-02-06 | 2011-06-15 | Neurofood Ab Oy | Koostumus psoriasiksen hoitoon |
| US20060062859A1 (en) * | 2004-08-05 | 2006-03-23 | Kenneth Blum | Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes |
| US20060241040A1 (en) * | 2005-04-06 | 2006-10-26 | Alberto Visintin | Methods of treating disorders associated with toll-like receptor 4 (TLR4) signalling |
| RU2308199C2 (ru) * | 2005-05-13 | 2007-10-20 | Закрытое акционерное общество "Компания "Нутритек" (ЗАО "Компания "Нутритек") | Продукт энтерального питания "нутриэн гепа" |
-
2007
- 2007-12-28 FI FI20075971A patent/FI122450B/fi not_active IP Right Cessation
-
2008
- 2008-12-17 EP EP08868549A patent/EP2234611B1/de not_active Not-in-force
- 2008-12-17 JP JP2010540153A patent/JP5378406B2/ja not_active Expired - Fee Related
- 2008-12-17 PL PL08868549T patent/PL2234611T3/pl unknown
- 2008-12-17 NZ NZ597976A patent/NZ597976A/xx not_active IP Right Cessation
- 2008-12-17 BR BRPI0821919-2A patent/BRPI0821919A2/pt not_active IP Right Cessation
- 2008-12-17 KR KR1020107016810A patent/KR20100103856A/ko not_active Application Discontinuation
- 2008-12-17 RU RU2010130889/15A patent/RU2462244C2/ru not_active IP Right Cessation
- 2008-12-17 DE DE08868549T patent/DE08868549T1/de active Pending
- 2008-12-17 CN CN2008801231858A patent/CN101917983B/zh not_active Expired - Fee Related
- 2008-12-17 US US12/810,150 patent/US20100291235A1/en not_active Abandoned
- 2008-12-17 NZ NZ586496A patent/NZ586496A/en not_active IP Right Cessation
- 2008-12-17 AT AT08868549T patent/ATE544450T1/de active
- 2008-12-17 NZ NZ597977A patent/NZ597977A/xx not_active IP Right Cessation
- 2008-12-17 AU AU2008345508A patent/AU2008345508B2/en not_active Ceased
- 2008-12-17 DK DK08868549.0T patent/DK2234611T3/da active
- 2008-12-17 ES ES08868549T patent/ES2381690T3/es active Active
- 2008-12-17 WO PCT/FI2008/050750 patent/WO2009083643A2/en active Application Filing
-
2010
- 2010-06-24 IL IL206596A patent/IL206596A0/en unknown
- 2010-10-26 HK HK10110064.8A patent/HK1143539A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008345508A1 (en) | 2009-07-09 |
| ATE544450T1 (de) | 2012-02-15 |
| RU2010130889A (ru) | 2012-02-10 |
| CN101917983A (zh) | 2010-12-15 |
| DK2234611T3 (da) | 2012-05-07 |
| EP2234611B1 (de) | 2012-02-08 |
| PL2234611T3 (pl) | 2012-07-31 |
| IL206596A0 (en) | 2010-12-30 |
| NZ586496A (en) | 2012-03-30 |
| AU2008345508B2 (en) | 2013-11-14 |
| RU2462244C2 (ru) | 2012-09-27 |
| EP2234611A2 (de) | 2010-10-06 |
| FI20075971A0 (fi) | 2007-12-28 |
| FI20075971A (fi) | 2009-06-29 |
| JP5378406B2 (ja) | 2013-12-25 |
| WO2009083643A3 (en) | 2009-10-29 |
| KR20100103856A (ko) | 2010-09-28 |
| WO2009083643A2 (en) | 2009-07-09 |
| NZ597976A (en) | 2012-08-31 |
| ES2381690T3 (es) | 2012-05-30 |
| BRPI0821919A2 (pt) | 2015-06-16 |
| JP2011507937A (ja) | 2011-03-10 |
| HK1143539A1 (en) | 2011-01-07 |
| NZ597977A (en) | 2012-08-31 |
| CN101917983B (zh) | 2013-08-21 |
| US20100291235A1 (en) | 2010-11-18 |
| FI122450B (fi) | 2012-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mathew et al. | ‘Magnesium’-the master cation-as a drug—possibilities and evidences | |
| EP2162153B1 (de) | Nahrungsergänzungen zur förderung von wachstum, reparatur und erhaltung von knochen und gelenken | |
| US20130337080A1 (en) | Dietary Supplements For Promotion of Growth, Repair and Maintenance of Bone and Joints | |
| JP6157572B2 (ja) | 神経変性または神経・筋変性疾患の治療方法およびその治療薬 | |
| KR101869185B1 (ko) | 혈액학적 장애의 치료에 사용하기 위한 glyt1 억제제 | |
| DE08868549T1 (de) | Zusammensetzung zur behandlung steriler entzündungen | |
| EP2968442B1 (de) | Neue stabile pentadecapeptidsalze, verfahren zur herstellung davon, verwendung davon zur herstellung von pharmazeutischen präparaten und therapeutische verwendung davon | |
| ATE466576T1 (de) | Zusammensetzung mit l-serin, l-isoleucin, folsäure und spurenelementen zur behandlung von psoriasis | |
| US10695437B2 (en) | Polycomplexes of poly-lysine compounds for preventing and/or combatting amyotrophic lateral sclerosis | |
| AU2016206154A1 (en) | Sulfonamide pharmaceutical composition | |
| KR20170072348A (ko) | 타우 단백질 생산 촉진제, 타우 단백질의 결핍에 기인한 질환의 치료약·예방약 및 치료용·예방용 식품 조성물 | |
| JPWO2017002895A1 (ja) | アミノ酸及び環状ジペプチドを含有する組成物 | |
| KR102292069B1 (ko) | 돌돔 인지질분해효소 유래의 항균 펩타이드를 유효성분으로 함유하는 암 치료용 약학적 조성물 | |
| Beckerly et al. | Pharmacologic Management of Complex Regional Pain Syndrome | |
| JP2024520753A (ja) | 神経原性炎症の予防または治療のための多イオン複合体 | |
| CN118176008A (zh) | 用于治疗创伤性脑损伤的香叶天竺葵提取物 | |
| WO2013121026A2 (en) | Intermittent treatment with oxidizing and reducing agents | |
| WO2011146036A1 (ru) | Лекарственное средство полиорганного протекторного действия для лечения состояний, обусловленных клеточной дисфункцией | |
| CA3100966A1 (en) | Inhibition of neurological disease | |
| WO2008134513A2 (en) | Copper lowering treatment of autoimmune diseases | |
| CN107929717A (zh) | 一种西拉美新与蛇毒细胞毒素‑ctx1的药物组合物 |